Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687906 · ClinicalTrials.gov registry record · Phase 1
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
A Phase 1 study of Bacterial Infections, sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC).
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 9
- Study locations
NCT02687906: Active Phase 1 study of Bacterial Infections, sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC).
NCT02687906 is a Phase 1 study of Bacterial Infections that is active but no longer recruiting, run by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC). The registered enrollment target is 39 participants, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (72% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687906, a Phase 1 study of Bacterial Infections, is active but no longer recruiting, sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 9
- Study locations
Study Summary
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Primary Outcome
AUC from time zero to infinity
Conditions Studied
Interventions
- DRUG Vabomere
Study Locations (9)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
- Rady Children's Hospital San Diego - San Diego
Ohio
- Rainbow Babies and Childrens Hospital - Cleveland
- Toledo Children's Hospital - Toledo
Arkansas
- Arkansas Children's Hospital - Little Rock
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Rutger's University - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-07 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT02687906 still lists
NCT02687906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 1 intervention - of which Vabomere is the first listed.
NCT02687906 lists 9 locations in 6 states (California, Ohio, Arkansas).
Frequently Asked Questions
What is clinical trial NCT02687906 about?
NCT02687906 is a clinical study titled "Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections". A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
What is the current status of trial NCT02687906?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2016-07. Estimated completion is 2025-12.
What conditions does trial NCT02687906 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT02687906?
The interventions under investigation include: Vabomere (DRUG).
Who is sponsoring clinical trial NCT02687906?
This trial is sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02687906 being conducted?
This trial has 9 study locations across Arkansas, California, Illinois, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02687906's enrollment target sits among peer trials
39 11th of 17 higher than 6 of 17 other Bacterial Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
-
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
COMPLETED · Phase 1
-
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
COMPLETED · Phase 1
-
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia